IMR Press / FBL / Volume 25 / Issue 10 / DOI: 10.2741/4885

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Resveratrol improves lipid metabolism in diabetic nephropathy rats
Show Less
1 Department of Pharmacy, Jing’ an District Centre Hospital of Shanghai (Huashan Hospital Fudan University Jing’ An Branch), Shanghaii, 200040, China
2 Department of Anesthesiology, Ruijin Hospital North, Shanghai Jiaotong University School of Medicine, Shanghai, 201821, China
Send correspondence to: Yonghong Zhao, Department of Pharmacy, Jing’ an District Centre Hospital of Shanghai. Address: No. 266, Xikang road, Jingan district Central Hospital, Jing’an district, Shanghai, China, Tel: 8609158183608; Fax: 02161578000, E-mail:
Front. Biosci. (Landmark Ed) 2020, 25(10), 1913–1924;
Published: 1 June 2020

Diabetic nephropathy (DN) is a major cause of chronic kidney disease characterized by insulin resistance and lipid deposition in tissues. To this end, we examined the effect of Resveratrol (RES) in streptozotocin (STZ) induced diabetic nephropathy. RES, in a dose dependent manner, decreased the insulin resistance, and improved kidney function and lipid metabolism in STZ treated rats. RES treatment increased p-AMPKα/AMPKα and p-ULK1 S777/ULK1 and the autophagy related proteins (Beclin1, LC3 II/I) and its effects on TC and improvement in insulin resistence were quenched by the inhibitor of autophagy, 3-MA. Together, these results suggest that the effect of RES in treatment of DN may involve AMPKα/mTOR-mediated autophagy.

lipid metabolism
insulin resistance
diabetic nephropathy
Figure 1
Back to top